

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1276)

PROPOSED ADOPTION OF THE 2026 H SHARE SCHEME

The board (the “**Board**”) of directors (the “**Directors**”) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, on August 19, 2026, the Board has resolved to propose the adoption of the 2026 H Share Scheme (the “**2026 H Share Scheme**”). The 2026 H Share Scheme shall become effective upon the approval at the forthcoming 2026 first extraordinary shareholders’ meeting of the Company (the “**Shareholders’ Meeting**”).

PROPOSED ADOPTION OF THE 2026 H SHARE SCHEME

The 2026 H Share Scheme enables the Company to grant awards in the form of restricted share units, and its purpose is (i) to improve the corporate governance structure, establish and enhance the long-term incentive mechanism of the Group; (ii) to recognize the contributions by the selected participants, including the Directors, senior management and other key personnel of the Company, and to provide them with an opportunity to acquire a proprietary interest in the Company through ownership of H shares of the Company listed on The Stock Exchange of Hong Kong Limited (the “**H Shares**”), so as to encourage and incentivize such persons and to closely align their interests with those of the Company and the shareholders of the Company (the “**Shareholders**”) as a whole; and (iii) to attract, motivate and retain suitable and skilled personnel for the continual operation, development and long-term growth of the Group, in order to promote the long-term, sustainable development and financial success of the Group.

The scheme limit of the 2026 H Share Scheme, being the total number of new H Shares, existing H Shares and/or treasury H Shares in respect of all awards that may be granted under the 2026 H Share Scheme, would be no more than 1,000,000 H Shares, representing no more than approximately 0.4% of the total number of issued H Shares (excluding any treasury shares) as at the adoption date of the 2026 H Share Scheme, assuming that no further H Shares will be allotted, issued, repurchased or cancelled from the date of this announcement up to the adoption date. The Company shall not make any further grant of awards which will result in the 2026 H Share Scheme limit being exceeded unless the Shareholders have approved a refreshment of the 2026 H Share Scheme limit or Shareholders’ approval has been obtained in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The adoption of the 2026 H Share Scheme is subject to, among other things, the passing of a special resolution at the Shareholders’ Meeting.

LISTING RULES IMPLICATION

The 2026 H Share Scheme is intended to be funded by new H Shares, existing H Shares and/or treasury H Shares of the Company. Therefore, the 2026 H Share Scheme will constitute a share scheme involving issue of new shares by the Company and the terms and conditions of which are required to comply with Chapter 17 of the Listing Rules.

SHAREHOLDERS' MEETING

The Company will convene and hold the Shareholders' Meeting to consider and, if thought fit, approve, among other matters, the proposed adoption of the 2026 H Share Scheme. A circular containing, among others, the details of the 2026 H Share Scheme, together with the notice of the Shareholders' Meeting, will be published on the websites of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company (www.hengrui.com) as soon as practicable.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
August 19, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.